| Not Yet Recruiting | A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patie Non-Small Cell Lung Cancer | Phase 3 | 2026-03-31 |
| Recruiting | HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma Advanced Gastric and Gastroesophageal Junction Adenocarcinoma | Phase 1 | 2026-01-29 |
| Not Yet Recruiting | A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. CRC | Phase 1 / Phase 2 | 2025-12-19 |
| Recruiting | Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid T Advanced Solid Tumors | Phase 1 | 2025-09-23 |
| Recruiting | Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer Advanced Prostate Cancer | Phase 1 | 2025-08-19 |
| Not Yet Recruiting | A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis Moderate-to-severe Plaque Psoriasis | Phase 3 | 2025-06-10 |
| Completed | A Drug-Drug Interaction Study Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets(Yasmin®) Psoriasis (PsO) | Phase 1 | 2025-05-28 |
| Active Not Recruiting | Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Osteosarcoma | Phase 3 | 2025-04-25 |
| Not Yet Recruiting | Phase I Study of HS-20108 in Participants With Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2025-04-17 |
| Recruiting | A Study of HS-20122 in Patients With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2025-04-15 |
| Not Yet Recruiting | A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis Psoriasis | Phase 2 | 2025-04-09 |
| Recruiting | HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer Ovarian Cancer | Phase 3 | 2025-03-13 |
| Recruiting | A Study of HS-20110 in Participants With Advanced Solid Tumors Solid Tumors | Phase 1 | 2025-02-26 |
| Not Yet Recruiting | ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma. Osteosarcoma, Soft Tissue Sarcoma (STS) | Phase 1 | 2024-12-20 |
| Recruiting | Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer | Phase 1 | 2024-12-14 |
| Withdrawn | ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 2 | 2024-11-30 |
| Not Yet Recruiting | A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis Psoriasis | Phase 3 | 2024-11-04 |
| Not Yet Recruiting | A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy Immunoglobulin a Nephropathy | Phase 2 | 2024-11-01 |
| Not Yet Recruiting | A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes Myelodysplastic Syndromes, Anemia, MDS | Phase 2 | 2024-10-30 |
| Recruiting | A Study of HS-20124 in Patients with Advanced Solid Tumors Solid Cancer | Phase 1 | 2024-10-30 |
| Recruiting | ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer Metastatic Colorectal Cancer (CRC) | Phase 1 | 2024-10-03 |
| Not Yet Recruiting | A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer Limited-stage Small-cell Lung Cancer | Phase 3 | 2024-09-30 |
| Recruiting | ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer Small Cell Lung Cancer | Phase 3 | 2024-07-04 |
| Not Yet Recruiting | A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women Vasomotor Symptoms | Phase 2 | 2024-05-30 |
| Recruiting | A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Non-Squamous Non-Small Cell Lung Cancer | Phase 2 / Phase 3 | 2024-05-28 |
| Recruiting | ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2024-04-26 |
| Recruiting | HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2024-04-11 |
| Not Yet Recruiting | Study of HS-20105 for Injection in Patients With Advanced Solid Tumors. Advanced Solid Tumor | Phase 1 / Phase 2 | 2024-03-01 |
| Recruiting | Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis Psoriatic Arthritis | Phase 2 | 2024-02-26 |
| Unknown | A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders Neuromyelitis Optica Spectrum Disorders | Phase 4 | 2024-02-25 |
| Recruiting | HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors Advanced Solid Tumor | Phase 2 | 2024-02-06 |
| Recruiting | ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Soli Metastasis Castration Resistant Prostate Cancer(mCRPC) | Phase 2 | 2024-01-18 |
| Recruiting | ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors Head and Neck Squamous Cell Carcinoma | Phase 2 | 2023-12-18 |
| Recruiting | HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | Phase 2 | 2023-12-18 |
| Unknown | Study of HS-10384 in Participants of Chinese Postmenopausal Women Vasomotor Symptoms | Phase 1 | 2023-11-12 |
| Unknown | A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis Psoriasis | Phase 2 | 2023-09-28 |
| Not Yet Recruiting | A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors Non-Small Cell Lung Cancer, Solid Tumor | Phase 1 | 2023-07-20 |
| Recruiting | ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas Osteosarcoma, Sarcoma | Phase 2 | 2023-06-08 |
| Recruiting | A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects IgA Nephropathy, Focal Segmental Glomerulosclerosis | Phase 1 | 2023-05-23 |